HRMY Profile
Harmony Biosciences Holdings Inc (HRMY) is a biopharmaceutical company that focuses on developing and commercializing novel therapies for patients with sleep and central nervous system disorders. The company is based in Plymouth Meeting, Pennsylvania, and was founded in 2017.
Harmony Biosciences Holdings' lead product, WAKIXÂ (pitolisant) is the first and only non-scheduled medication approved by the US Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. Narcolepsy is a chronic, neurological sleep disorder that affects approximately one in every 2,000 people in the United States.
The company's pipeline also includes other drug candidates that are being developed for various sleep and CNS disorders, such as EDS and Rett syndrome. The company is focused on developing new therapies to help patients with unmet medical needs.
In addition to its research and development efforts, Harmony Biosciences is also committed to engaging with patients, caregivers, and advocacy groups to raise awareness about sleep and CNS disorders and to improve access to care. The company also provides educational resources and support programs to help patients and their families manage their conditions.
Harmony Biosciences Holdings went public in 2020 and is listed on the NASDAQ exchange under the ticker symbol HRMY. The company has partnerships with various academic institutions, research organizations, and biopharmaceutical companies to advance its research and development efforts.
|
